5 results about "Dipyridamole" patented technology

The invention belongs to the technical field of biological medicine, and relates to an anticoagulant, in particular to an anticoagulant for a high-precision animal blood cell analyzer and application of the anticoagulant in leukocyte classification. The anticoagulant comprises a buffer and anticoagulation matrix component and an active component, wherein in every 100 mL of the anticoagulant, the buffer and anticoagulation matrix component formula comprises 1.5 to 2 g of citrate, 0.3 to 0.5 g of citric acid and 0.15 to 0.20 g of EDTA-K2 (Ethylene Diamine Tetraacetic Acid), and the active components comprise 0.08 to 0.10 g of low molecular weight enzymolysis carboxymethyl chitosan, 1.0 to 1.2 g of hydroxypropyl-beta-cyclodextrin, 10 to 15 mg of dipyridamole and 8 to 10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and leukocyte morphological deformation, realizes accurate identification in leukocyte five-classification, has a classification accuracy rate of 98%, and is suitable for veterinary clinical hematology examination and animal epidemic disease monitoring.

To provide novel agents for the treatment or prevention of Epstein-Barr virus hepatitis. [Solution] A pharmaceutical composition for the treatment or prevention of Epstein-Barr virus hepatitis in a subject, comprising ibudilast, dipyridamole, or both as active ingredients.

The application belongs to the technical field of biological medicine, and relates to an anticoagulant and application thereof in white blood cell classification for high-precision animal blood cell analyzers. The anticoagulant comprises two parts of buffer and anticoagulant matrix components and active components. In the anticoagulant, the buffer and anticoagulant matrix component formula comprises 1.5-2 g of citrate, 0.3-0.5 g of citric acid and 0.15-0.20 g of EDTA-K2 per 100 mL of the anticoagulant, and the active component comprises 0.08-0.10 g of low-molecular enzymatic hydrolysis carboxymethyl chitosan, 1.0-1.2 g of hydroxypropyl-beta-cyclodextrin, 10-15 mg of dipyridamole and 8-10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and white blood cell morphological deformation, accurately identifies in white blood cell five classification, and has a classification accuracy as high as 98%, and is suitable for veterinary clinical hematology examination and animal disease monitoring.

The invention discloses a pharmaceutical composition for cardiovascular and cerebrovascular diseases, and relates to the technical field of traditional Chinese medicines, the pharmaceutical composition comprises the following raw materials by weight: 150-250 parts of panax notoginseng saponins, 8-12 parts of ginkgo total flavonoids, 3-5 parts of dipyridamole, 80-120 parts of a salvianolic acid extract, 5-15 parts of astragaloside, 20-40 parts of a composition of saikoside a and albiflorin, and 30-50 parts of a composition of ginsenoside Rg1 and ophiopogonin D; according to the pharmaceutical composition, the system treatment rule of eliminating, clearing, lowering, warming, harmonizing and tonifying in the traditional Chinese medicine is completely and quantitatively applied to the design of the modern traditional Chinese medicine compound composition for the first time, so that the abstract theory is converted into specific quantifiable components and proportions, and the problem that the traditional compound is not clear and unclear is solved; all the components in the composition are safe components which are recorded in pharmacopoeia or are clinically used for a long time, and potential risks caused by large-dose use of a single component can be reduced through reasonable compatibility and mutual restriction.

The invention discloses application of dipyridamole and a preparation thereof in prevention and treatment of atopic dermatitis. In the application, the inventor discovers the application of the dipyridamole or the derivative thereof in preparation of medicines for prevention, adjuvant therapy or treatment of atopic dermatitis, the dipyridamole cream and gel are developed on the basis of the application, the formula of the dipyridamole cream and gel is further optimized, and the dipyridamole cream and gel can be used for preparing the medicine for preventing, adjuvant therapy or treatment of atopic dermatitis. The permeability of the dipyridamole and the treatment and prevention effects of the dipyridamole on mice with atopic dermatitis can be obviously improved by adding the diethylene glycol monoethyl ether and the polyethylene glycol-7-stearate into the oil phase. The dipyridamole external preparation is safe, non-irritant and more friendly to a human body, the color is obviously closer to the skin color of the human body after color mixing, the visual sense organ effect is good, and the dipyridamole external preparation is easily accepted by patients.